65
Participants
Start Date
September 16, 2015
Primary Completion Date
June 19, 2019
Study Completion Date
June 19, 2019
Risankizumab 600 mg IV
Re-induction treatment; 3 infusions every 4 weeks, after which eligibility was assessed if clinical response was re-gained
Risankizumab 180 mg SC
Maintenance treatment every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.
ULB Erasme /ID# 154987, Brussels
Cliniques Universitaires Saint Luc /ID# 154985, Woluwe-Saint-Lambert
Imelda Ziekenhuis /ID# 154984, Bonheiden
UZ Leuven /ID# 154986, Leuven
CHU de Liege /ID# 154988, Liège
AZ Groeninge /ID# 154989, Kortrijk
AZ-Delta /ID# 154983, Roeselare
MGG Group, Inc.Chevy Chase Clinical Research /ID# 155068, Chevy Chase
Hospital Univ de la Princesa /ID# 155065, Madrid
Med Hochschule Hanover /ID# 155041, Hanover
Yeungnam University Med Ctr /ID# 155056, Daegu
Clin Res Inst of Michigan, LLC /ID# 155066, Chesterfield
Universitaetsklinikum Erlangen /ID# 155039, Erlangen
McMaster University Med Cent /ID# 155019, Hamilton
Academisch Medisch Centrum /ID# 155058, Amsterdam
Maastricht Universitair Medisch Centrum /ID# 155059, Maastricht
NZOZ Vivamed /ID# 155061, Warsaw
Lexmedica /Id# 155062, Wroclaw
Kangbuk Samsung Hospital /ID# 155054, Jongno-Gu
Severance Hospital /ID# 155055, Seoul
Asan Medical Center /ID# 155053, Seoul
Hospital Duran i Reynals /ID# 155063, L'Hospitalet de Llobregat
Hospital Clinic de Barcelona /ID# 155064, Barcelona
Guy's and St Thomas' NHS Found /ID# 155046, London
Addenbrookes Hospital /ID# 155047, Cambridge
St. James University Hospital /ID# 155050, Leeds
The Newcastle Upon Tyne Hospitals NHS Foundation Trust' /ID# 155049, Newcastle upon Tyne
John Radcliffe Hospital /ID# 155048, Oxford
Lead Sponsor
Collaborators (1)
Boehringer Ingelheim
INDUSTRY
AbbVie
INDUSTRY